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(by R$1,011) and effectiveness (by 2.7%) were greater compared to VAN, resulting in 
an ICER of R$37,564 per successfully treated patients. But compared to TEI, LZD had 
lower costs (by R$2,246) and greater effectiveness (by 13.3%), with LZD being the 
‘dominating’ treatment. Majority of treatment costs were related to hospital stay, 
primarily ICU (73% in private and 50% in public scenario). Several scenarios were 
tested by varying treatment duration (7or14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). Results for all scenarios were similar to the base 
case from public and private perspectives. CONCLUSIONS: From private perspective 
LZD is a cost-effective alternative to VAN and TEI for treatment of MRSA-confirmed 
NP, owing primarily to its higher clinical response rate. From public perspective, LZD 
can be considered cost effective since its ICER vs. VAN is within 2-3 times Brazil’s 
GDP per capita.
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OBJECTIVES: The objective of the review was to determine the most widely used 
estimates of United States (US) costs of different stages of liver disease in patients 
with hepatitis C virus (HCV) in cost-effectiveness analyses (CEA). METHODS: A 
systematic literature search using predetermined search terms was performed 
to identify English-language articles that report cost or CEA from 1995 to 2014. 
Full texts were obtained and reviewed to determine study eligibility on the basis 
of predefined inclusion and exclusion criteria. All costs were inflated to 2014 
values. RESULTS: A total of 53 articles were eligible for review. In primary cost 
studies, two methods were generally used to derive the disease state costs: 
microcosting using treatment algorithms and unit costs; or statistical analyses 
of observational databases. The most widely used primary cost estimates in CEAs 
completed before 2011 were those derived using treatment algorithms by Bennett 
and colleagues (1997). A CEA published in 2012 by Gellad and colleagues presented 
updated resource use and costs for all the disease stages based on the Bennett 
study and added mild/moderate chronic HCV, compensated cirrhosis, and post-
SVR health states. The most widely used primary cost estimates in CEAs completed 
after 2012 are those obtained from a large database study by McAdam-Marx and 
colleagues (2011). This study provides estimates for all liver stages but does not 
include subcategories for decompensated disease. The estimates from the dif-
ferent sources were quite different; for example, for cirrhosis and hepatocellular 
carcinoma Gellad estimated $745 and $45,728 per year while McAdam-Marx esti-
mated $2,584 and $50,658 per year, respectively. CONCLUSIONS: There are many 
estimates of costs of HCV liver disease and these estimates can vary widely due 
to differences in study methodology. Understanding the differences in these esti-
mates can aid in the selection of the most appropriate inputs for use in economic 
models.
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OBJECTIVES: AASLD/IDSA have recently updated their treatment guidelines to 
include sofosbuvir-based therapy as recommended regimen for treatment-naïve and 
previously treated patients with hepatitis C (HCV) genotype 1 infection. The purpose 
of the study was to compare the cost-effectiveness of sofosbuvir-based combination 
therapies vs. peg-IFN and ribavirin (PEGIFN) among treatment-naïve patients and 
compare sofosbuvir-based combinations with and without interferon among patients 
previously treated with PEGIFN. METHODS: Cost per sustained viral response (SVR) 
was performed using a decision tree. It was assumed that patients were equally likely 
to receive either treatment. The model contained clinical data from Phase III clinical 
trials for PEGIFN (T1), sofosbuvir triple therapy (T2) (NEUTRINO study), and sofos-
buvir plus simeprevir and/or ribavirin (T3) (COSMOS study); drug and medical costs 
were obtained from the National Average Drug Acquisition Costs Database (Medicaid) 
and literature. Time horizon was 48 weeks for both analyses. RESULTS: Average cost 
among the treatment-naïve was $79,749 for T1 arm (52% SVR), $101,317 for T2 (91% 
SVR), and $147,386 for T3 (94% SVR). Among the pre-treated, the average cost was 
$142,862 for T2 (72% SVR) and $187,664 for T3 (94% SVR). Among the treatment-naïve, 
an ICER of $553 and $719 per 1%SVR gain was obtained for T2 vs. T1 and T3 vs. T1, 
respectively. Among the pre-treated, an ICER of $2036 per 1%SVR was obtained for T3 
vs. T2. In sensitivity analysis, no other factor but %SVR impacted incremental costs 
per responder. CONCLUSIONS: Although sofosbuvir-based combination without 
interferon was found to be the most expensive treatment it achieved the highest 
SVR rates among treatment-naive and pre-treated patients. The presented results 
can be used to make decisions by individual payers’ based on their willingness to pay 
thresholds. Future studies should examine the cost-effectiveness of new therapies 
by relevant HCV patient subgroups.
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OBJECTIVES: A 2010 randomized controlled trial, the first in the United States (US), 
was carried out to study the clinical effectiveness of pre-exposure HIV prophylaxis 
(PrEP) among men-who-have-sex-with-men (MSM) population over a follow up of 
diagnosis and treatment of hospitalized patients with infections carries a significant 
cost and suggests potential benefits in reducing time to diagnosis.
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OBJECTIVES: Malaria treatment in health care facility represents a standard prac-
tice in malaria case management. The study estimated the costs of treatment for 
uncomplicated malaria from a healthcare facility, to generate current information 
for appropriate decision making in resource or funding allocations for malaria 
treatment and control in Nigeria. METHODS: Based on a comprehensive cost of 
illness approach, hospital associated costs of uncomplicated malaria episodes 
were estimated from a provider perspective, applying a standard costing procedure 
for outpatient services. Capital and recurrent expenditures were estimated using 
ingredient approach combined with step-down methodology to calculate the final 
costs. Costs attributable to malaria treatment were calculated based on the propor-
tion of uncomplicated malaria cases treated within in the period. Non-hospital 
costs were not collected. Total and average financial and economic costs were 
estimated for uncomplicated malaria. All costs were calculated in local currency, 
converted to the US Dollars at the 2013 exchange rate. RESULTS: The hospital 
spent a total annual economic cost of N31.612 million (US$201,352.30) for the treat-
ment of uncomplicated malaria, at US$34.66 per case. This represents about 20% of 
the hospital total expenditure within the year. Personnel accounted for over 81% of 
the expenditure as the dominant cost driver, followed by antimalarial drugs, 7.8%. 
Over 45% of outpatients visits were treated for malaria in the facility, leading to 
increased utilization of hospital resources. Changes in personnel costs, drug prices 
and malaria prevalence significantly impacted on the study results, indicating the 
need for improved efficiency in the hospital resource utilization. CONCLUSIONS: 
Malaria treatment at the medical center constitutes a considerable amount of 
hospital expenditure, arising mainly from the cost of personnel and high propor-
tion of malaria treatment. For a more effective healthcare system, there is need 
for more efficient use of hospital resources to prevent wastages and reduce costs 
to the provider and consumer.
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OBJECTIVES: This study sought to estimate the average outpatient cost of providing 
adult antiretroviral therapy (ART) at an urban care centre for the ﬁrst year following 
ART initiation. METHODS: A retrospective, ingredients-based costing approach was 
implemented, as previously described in literature. Medical records for a conveni-
ent sample of 120 patients were reviewed 1 year after ART initiation. Subjects were 
assigned to any one of the following outcome categories based on their status at 
the end of the study period: in care and responding (IC); in care but not responding 
(NR); or no longer in care at study site (NIC). Average cost per outcome category 
was estimated based on resource utilisation, in 2013 US$. RESULTS: The overall 
annual retention in care was 93.3%. At the end of the first 12 months of ART care, 
109 (90.8%) of the patients were IC, 7 (6.7%) patients were NIC and 3 (2.5%) patients 
were NR. The average outpatient cost per patient initiated was USD $461. The costs 
were structured as follows; outpatient visits (49.2%), medications (26.4%), laboratory 
tests (21.8%) and fixed costs (2.6%). The average cost to produce an IC patient was 
US$ 472, NR US$ 438 and NIC US$ 322. The average cost of producing a patient in 
care and responding to ART represented 49.2% of the country’s GDP per capita for 
2013. This estimate excludes building and utility costs because they were unavail-
able, hence the actual average cost may be higher. CONCLUSIONS: These findings 
show that maintaining an HIV/AIDS patient in care and responding to ART is an 
expensive undertaking relative to the country’s GDP per capita. This underscores 
the need for periodic costing studies as a way of continually monitoring the costs 
and cost structures associated with caring for people living with HIV and AIDS, as 
this would aid in planning and decision-making.
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OBJECTIVES: To evaluate economic impact of linezolid (LZD) versus vancomy-
cin (VAN) and teicoplanin (TEI) for treatment of confirmed methicillin-resistant 
Staphylococcus aureus (MRSA) nosocomial pneumonia (NP) in Brazilian private 
and public healthcare systems. METHODS: A 4 week decision model was developed 
capturing 1st and 2nd line therapy. Published literature, local sources, and expert 
opinion provided clinical and resource use data, such as efficacy, mortality, adverse 
events (AEs), treatment duration, and length of hospital/ICU stay. Brazil cost data 
was obtained from local published sources and micro-costing. Base-case analysis 
used 14-day treatment duration. In event of treatment failure/severe AEs on 1st-line 
therapy, drug was switched after 7 days. Costs were reported in 2014 Brazilian Real. 
Scenario based sensitivity analyses were conducted. RESULTS: From private per-
spective, LZD was associated with lower costs (by R$5,760 and R$10,551), and greater 
overall treatment success (by 2.7% and 13.3%) compared to VAN and TEI respectively, 
resulting in LZD ‘dominating’ both treatments. From public perspective, LZD costs 
